The DIM “Thérapie Génique”, coordinated by Pr Marina Cavazzana, is a network of public and private stakeholders labelled by the Paris Region in 2017 for a time-period of 4 years to accelerate the development of gene therapy. The financed research projects in the field of gene therapy aim to bring multidisciplinary expertise with the prospect of clinical trials and to develop promising therapeutic approach becoming innovative solutions available for patients.
Imagine Institute of Genetic Diseases is a research and innovative healthcare institute of a new type. Located on the campus of the Necker Enfants Malades Hospital in Paris, it brings together, around the patients, over 900 researchers, physicians and healthcare professionals, with the aim to better understand, diagnose, and treat genetic diseases. At the forefront of experimental and clinical expertise in gene therapy, Imagine Institute manages the DIM «Thérapie Génique» network.
Medicen Paris Region is a leading European life sciences’ cluster. With more than 400 members, Medicen is a unique forum connecting ALL of the stakeholders that INNOVATE in Healthcare: research institutes, start-ups and SMEs, incubators, large companies and physicians.
The role of Medicen is to foster healthcare innovation and the economic development of Paris Region, strengthening the international competitiveness of the French “health and leading-edge health technology” sector. Its activities are structured around 5 strategic areas: In vitro diagnostics, Diagnostic and Interventional Imaging, ICT for Health, Translational medicine and Regenerative Medicine and Biomaterials (including cell, therapy, gene therapy, biomaterials and tissue engineering).
Enterprise Europe Network (EEN) is the largest information, consultancy and support network for small and medium-sized enterprises (SMEs) with international ambitions in Europe. The Network is active in more than 60 countries worldwide. It brings together 3,000 experts from more than 600 member organisations – all renowned for their excellence in business support. Member organisations include: technology and innovation clusters, support agencies, universities and research institutes, regional development organisations, chambers of commerce and industry. The Network’s international business experts have the experience and ressources to help business grow and to offer advisory services and innovation support.
The Cell and Gene Therapy Catapult was established as an independent centre of excellence to advance the growth of the UK cell and gene therapy industry, by bridging the gap between scientific research and full-scale commercialisation. With more than 160 employees focusing on cell and gene therapy technologies, it works with partners in academia and industry to ensure these life-changing therapies can be developed for use in health services throughout the world. It offers leading-edge capability, technology and innovation to enable companies to take products into clinical trials and provide clinical, process development, manufacturing, regulatory, health economics and market access expertise. Its aim is to make the UK the most compelling and logical choice for UK and international partners to develop and commercialise these advanced therapies. The Cell and Gene Therapy Catapult works with Innovate UK. For more information please visit ct.catapult.org.uk or visit www.gov.uk/innovate-uk.
The UK Science and Innovation Network (SIN)
Science and innovation play an important role in encouraging prosperity and growth through the UK Science and Innovation Network (SIN). The UK is a global leader in science and innovation. International collaboration is essential to maintaining the excellence of the UK’s research base and the competitive advantage of our innovative businesses, for filling capability gaps and for ensuring value by leveraging international resources. Maintaining our science excellence (and our reputation) and supporting innovation ensures the UK is a partner of choice, and helps UK companies with ambitions for rapid global growth.
The Department for International Trade (DIT)
DIT is an international economic department, responsible for bringing together policy, promotion and financial expertise to break down barriers to trade and investment, and help businesses succeed. The UK has one of the most vibrant and productive life science sectors in the world. With nearly 5,000 companies, a proven track record of scientific achievement, and strong government commitment, the UK leads Europe in life science financing and is the number one choice for European HQs. We support overseas companies bringing their high-quality investments to the UK’s dynamic economy.
EIT Health promotes healthy living, active ageing and improvements in healthcare.
EIT Health France is headquartered in Paris, a vibrant financial and economic center with a long record of innovation and business incubation and a highly developed and dynamic innovation ecosystem. It includes a strong community of existing clusters and incubators with innovative startups, SMEs and joint teams from major academic and industrial stakeholders. It gathers excellent partners from the health ecosystems, with industrial partners in big pharma, medtech, biotech, healthcare and big data companies, as well as academic partners like leading universities and research institutes.
In 2017 it launched “the Innovation Journey from Education to Business”, a project designed to support collaboration and to create opportunities between owners of problems, providers of solutions and the EIT Health ecosystem – especially regarding the societal challenges of sleep disorders and gathering real life data in sustainable cities.